• Essa Pharma Inc. will be presenting at the 2024 Cantor Global Healthcare Conference on September 18, 2024, at 9:10 a.m.
• The presentation will focus on developing novel therapies for prostate cancer treatment.
• Wood will participate in a fireside chat.
• A live webcast of the fireside chat can be accessed on ESSA.
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. ET in New York, NY.
David R. Parkinson, President and Chief Executive Officer, Peter Virsik, Chief Operating Officer and Executive Vice President, and David S. Wood, Chief Financial Officer, will participate in a fireside chat.
A live webcast of the fireside chat can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essaphrma.com, and follow us on X and LinkedIn.
Contacts
ESSA Pharma Inc.
Peter Virsik, Chief Operating Officer
778.331.0962
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors and Media:
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.05 |
| Daily Change: | -0.72 -10.64 |
| Daily Volume: | 115,471 |
| Market Cap: | US$268.440M |
September 13, 2024 August 05, 2024 May 14, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
